



Sir Chris Bryant MP
Minister of State for Trade
Department for Business and Trade

Old Admiralty Building
Admiralty Place
London
SW1A 2DY
United Kingdom

T +44 (0) 20 4551 0011
E Bryant.Correspondence@businessandtrade.gov.uk
W gov.uk

The Rt Hon Liam Byrne MP

Chair of the Business and Trade Committee
House of Commons
London
SW1A 0AA

2 April 2026

Dear Liam,

UK-US Arrangement on Pharmaceuticals Pricing and Tariffs

I am pleased to update the Business and Trade Committee on the UK-US Arrangement on Pharmaceuticals Pricing and Tariffs, which the Government will publish shortly. An embargoed copy of the arrangement has been shared with the Science, Innovation and Technology and the Health and Social Care Committees by the Minister for Science, Research and Innovation and the Parliamentary Under-Secretary of State for Health Innovation and Safety before publication.

This arrangement has been made in the best interests of patients, the UK economy, and our Life Sciences sector.

More NHS patients will get improved access to life-changing new treatments because of the medicines pricing changes we have made, and the associated UK medicines spend targets set out in the arrangement. In addition, the arrangement includes clarification of the US commitments on its Most Favoured Nation (MFN) pricing policy and supporting UK patient access; including outlining expectations from the US government that companies will continue to launch new medicines quickly in the UK.

UK pharmaceuticals and medical technology exports will be subject to no additional US tariffs as a result of US Section 232 or Section 301 investigations for at least 3 years. This makes the UK the first country to secure tariff free access to the US pharmaceuticals market, providing certainty for UK exporters, and gives the UK sector a competitive advantage over other trading partners.

The arrangement will support UK economic growth and help protect our vital pharmaceutical manufacturing industry - which in 2025 added £28.5bn to the UK economy, employed over 50,000 people in high-skilled jobs across the country and exported almost £21bn in pharmaceutical products worldwide, 25% of which went to the US. This also protects over 195,000 UK jobs in the MedTech sector.

The arrangement does not introduce any further costs for HM Government beyond those set out previously. The Government will continue to assess the costs and benefits of this arrangement.

Senior officials will be available to provide further briefing on this matter. I look forward to continuing to work closely with the Committee going forward.

Yours sincerely,

A handwritten signature in black ink, reading "Chris Bryant". The signature is fluid and cursive, with the first name "Chris" and the last name "Bryant" clearly legible.

Sir Chris Bryant MP
Minister of State for Trade
Department for Business and Trade